

Product datasheet for TL309911

RBM4 Human shRNA Plasmid Kit (Locus ID 5936)

Product data:

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Product Type:	shRNA Plasmids
Product Name:	RBM4 Human shRNA Plasmid Kit (Locus ID 5936)
Locus ID:	5936
Synonyms:	LARK; RBM4A; ZCCHC21; ZCRB3A
Vector:	pGFP-C-shLenti (TR30023)
E. coli Selection:	Chloramphenicol (34 ug/ml)
Mammalian Cell Selection:	Puromycin
Format:	Lentiviral plasmids
Components:	RBM4 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 5936). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
RefSeq:	NM 001198843, NM 001198844, NM 002896, NM 002896.1, NM 002896.2, NM 002896.3, NM 001198843.1, NM 001198844.1, BC032735, BC032735.1, BC000307, BC021120, BC064960, NM 001198844.2, NM 002896.4
UniProt ID:	Q9BWF3



This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2023 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US

ORIGENE RBM4 Human shRNA Plasmid Kit (Locus ID 5936) – TL309911

Summary:	RNA-binding factor involved in multiple aspects of cellular processes like alternative splicing of pre-mRNA and translation regulation. Modulates alternative 5'-splice site and exon selection. Acts as a muscle cell differentiation-promoting factor. Activates exon skipping of the PTB pre-mRNA during muscle cell differentiation. Antagonizes the activity of the splicing factor PTBP1 to modulate muscle cell-specific exon selection of alpha tropomyosin. Binds to intronic pyrimidine-rich sequence of the TPM1 and MAPT pre-mRNAs. Required for the
	translational activation of PER1 mRNA in response to circadian clock. Binds directly to the 3' UTR of the PER1 mRNA. Exerts a suppressive activity on Cap-dependent translation via binding to CU-rich responsive elements within the 3' UTR of mRNAs, a process increased under stress conditions or during myocytes differentiation. Recruits EIF4A1 to stimulate IRES- dependent translation initiation in respons to cellular stress. Associates to internal ribosome entry segment (IRES) in target mRNA species under stress conditions. Plays a role for miRNA- guided RNA cleavage and translation suppression by promoting association of AGO2- containing miRNPs with their cognate target mRNAs. Associates with miRNAs during muscle cell differentiation. Binds preferentially to 5'-CGCGCG[GCA]-3' motif in vitro.[UniProtKB/Swiss- Prot Function]

shRNA Design:These shRNA constructs were designed against multiple splice variants at this gene locus. To
be certain that your variant of interest is targeted, please contact techsupport@origene.com.If you need a special design or shRNA sequence, please utilize our custom shRNA service.

PerformanceOriGene guarantees that the sequences in the shRNA expression cassettes are verified toGuaranteed:correspond to the target gene with 100% identity. One of the four constructs at minimum are
guaranteed to produce 70% or more gene expression knock-down provided a minimum
transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to
evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly
assess knockdown, the gene expression level from the included scramble control vector must
be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2023 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US